Tempus is the latest venture of businessman and philanthropist Eric Lefkofsky. His new venture has managed to secure $70 million dollars in its latest series C venture capitalist funding round. The investors in this latest round include Revolution Growth and New Enterprise Associates.
This latest $70 million dollar cash infusion brings the total number of dollars invested in Tempus to date to $130 million. Tempus is now valued at more than $700 million dollars. It was launched in 2015 by Eric Lefkofsky and a business partner.
Eric Lefkofsky serves as the chief executive officer at Tempus. He has also personally invested considerable funds into Tempus at each funding round. Lefkofsky and his business partner are in fact the single biggest investors in the venture so far. Mr. Lefkofsky has also pledged to invest up to $100 million dollars of his own money into Tempus to see it grow and succeed.
It may seem bizarre that Eric Lefkofsky is now investing in and launching a new healthcare company. After all, he became a billionaire by creating companies and investing in the tech sector and not the healthcare sector. Well, Mr. Lefkofsky has seen a close relative of his afflicted with cancer. He saw the limitations firsthand of the amount of information available regarding cancer treatment. This led him to create Tempus.
So what does Tempus actually aim to do? The company aims to use the latest technology to gather and analyze large amounts of medical data that medical doctors and researchers can then use to treat and study cancer. It is hoped that with more access to information, doctors can then more effectively treat patients with cancer. Eric Lefkofsky has said that the field of oncology or the study of cancer, has historically suffered from a lack of data organization and dissemination. Tempus is looking to change that with its new technology. It also looking to help both doctors and patients that are battling cancer.
To further its goal, Eric Lefkofsky has announced major partnerships with prominent healthcare organizations. They include the Mayo Clinic, The Duke University School of Medicine and the Cleveland Clinic. Together Tempus hopes to build a library of medical data that physicians across the country can use to treat chronic disease such as cancer.
If you want to start a business, you need to have a plan for success. A lot of people have the passion to start a business, but without a plan you will end up with a lot of wasted time and money. Eric Lefkofsky is the type of person who is always willing to take a chance in order to get where he needs to go in life. Not only does he have a track record of success in helping others, but he truly believes in the work that he is doing for his clients. There are a lot of people who are excited about the changes that he is most successful entrepreneurs making to his business. If you want to invest for the future, Eric Lefkofsky is a person to learn from.
From the time that he started his first business, Eric Lefkofsky has always wanted to make an impact on the world. There are a lot of people who look up to his hard work and success in variety of areas. Not only does he truly care about clients, but he wants to help them in a variety of ways as well. There are a lot of people who want to invest for their future in a new business. Not only can this help drive growth, but it can also help you figure out what is best for your future. There are many people who are excited about treatment work that he is doing with his companies.
In the coming years, Eric Lefkofsky wants to help as many clients as possible. Not only can this drive growth for the future, but Eric Lefkofsky wants to make a major impact on the world as well.
A lot of people are excited about the changes that are coming for Eric Lefkofsky and his companies. He knows that he will be able to help others through his work, and that is the passion that keeps him going when things get tough.
To know more visit @: www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html
One of the greatest mysteries that have evading humanity is the mystery of aging. Hundreds of doctors and philosophers have pondered the curiosity that is aging. As technology evolves, more doctors are beginning to understand the aging process on wikipedia.org. Obviously, there’s no cure for aging right now, but there is research supporting the theory that there will be one day. One of the leading researchers on this matter is Mikhail V. Blagosklonny, M.D., Ph.D. Like many before him, Mikhail became fascinated by aging as a young person. There’s clearly an urge in all humans to want to stay young but what evidence supports the reality of that.
Currently, Mikhail Blagosklonny is a professor of oncology at Roswell Park Cancer Institute. Having an interest in medicine and anatomy from a young age, Mikhail has spent much of his adult life in the medical field. He attended the First Pavlov State Medical University of St. Peterburg. He earned both his M.D. and Ph.D. from St. Peterburg. First, he received his M.D. in internal medicine. Second, he received his Ph.D. in experimental medicine and cardiology. After graduating, New York Medical College named him their associate professor of medicine. He held that position for a few years before moving on to being a senior scientist at Ordway Research Institute at https://www.linkedin.com/in/mikhail-blagosklonny-91abb531. It was in 2009 that he accepted his current position at Roswell Park Cancer Institute.
Most of what Mikhail studies are cancer therapies. These kinds of treatments are designed to protect normal, healthy cells from being damaged. In researching cancer therapies, he began studying the fundamental mechanisms of aging. He also studies the anti-aging drugs that pharmaceutical and beauty companies are creating nowadays. Mikhail Blagosklonny keeps track of his studies as editor-in-chief of several science journals. He oversees articles for Aging, Cell Cycle, and Oncotarget. He’s also on the editorial board of a well-known science journal, the Cell Death and Differentiation.
Dr. Mikhail Blagosklonny has written over 200 articles about his researched interests. His peers review all of his articles. Lately, his primary focus has been on cellular biology. He does continue to write about other subjects, such as clinical investigations. What science has learned about aging over the last decade is that it occurs on a cellular level on tandfonline.com. No one can pinpoint why cells age, but there does seem to be a way to slow its aging process.
Decades have passed with a strong push for a cure for cancer, yet despite the amount of money that has been raised for finding a cure, it has never come to fruition. Seattle Genetics, a company that has pioneered antibody-based therapies. These therapies have been heavily researched for the sole purpose of killing cancer cells. While many different drugs have come to the forefront, this time, Seattle Genetics may be the winner.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Additionally, the highlight of this type of therapy is that it is designed to spare those cells that are non-cancerous. The main goal that has been set in order to raise the bar on more holistic therapies, is that chemotherapy would no longer be deemed the first choice for cancer patients. The miracle of meeting unmet needs in the medical field would be an accomplishment, but additionally, it would epitome of medical research as we know it.
These drugs, known as antibody-drug conjugates, or ADC’s, are making headlines as the research and trials continue with the company. This could means that these drugs could potentially become the anti-tumor solution that doctors and patients have been searching for. The treatment level for cancer thus far has included various types of lymphomas include CD30-expressing lymphomas, Hodgkin’s lymphoma, cutaneous T-cell lymphoma, and many others.
Additional trials will also include an ADC that is designed to target various other types of cancers including leukemia, hematologic malignancies, and various types of tumors. The clinical research and trials that are being run by Clay Siegall at